Brand head-to-head · the one trial that answered it
Zepbound vs Wegovy in 2026: the head-to-head verdict, the price ladders, and who should pick which
This is the rare brand-versus-brand question with a direct randomized answer: SURMOUNT-5 put tirzepatide (Zepbound) head-to-head against semaglutide (Wegovy) and reported roughly 20.2% versus 13.7% average weight loss at 72 weeks — a decisive efficacy verdict for Zepbound, delivered in the same trial rather than across incomparable studies. But 2026 buying decisions run on three more axes. Indications: Zepbound uniquely carries the obstructive-sleep-apnea indication — a coverage lever — while Wegovy’s cardiovascular-outcomes label (SELECT) does the same job on the other side, and Wegovy alone offers an oral form. Price structure: both live under the $50 Medicare Bridge and ~$25 commercial cards; the self-pay ladders diverge — Zepbound’s LillyDirect vials at $299/$399/$449 with the 45-day refill trap ($849–$1,049 off-window), Wegovy’s NovoCare lane with promo-then-$349-class pricing. Tolerability: same GI-led class profile, individually unpredictable — the honest tiebreaker only when the first three axes tie. Full decision file below. (Compounded counterparts use the same active ingredients; not FDA-approved as finished drugs.)
The head-to-head trial — why this comparison is unusually clean
Most “drug A vs drug B” content launders cross-trial numbers with different populations and endpoints; the reread file exists to catch that. SURMOUNT-5 removed the excuse: one trial, randomized, tirzepatide’s maximum tolerated dosing against semaglutide’s, 72 weeks — ~20.2% versus ~13.7% average loss, with higher-threshold responses (≥20%, ≥25%) favoring tirzepatide by wide margins. Mechanistic story: dual GIP/GLP-1 agonism versus GLP-1 alone. The honest caveats that survive even a clean trial: averages aren’t destinies — semaglutide’s distribution contains deep responders, tirzepatide’s contains modest ones — and “maximum tolerated” means titration discipline matters on both arms. But as class verdicts go, this one is about as unambiguous as obesity medicine gets: on average, at full dosing, tirzepatide loses meaningfully more weight.
Indications and forms — the labels that unlock coverage
Efficacy sells the molecule; labels unlock the coverage. Zepbound’s edge: the OSA indication — approved on SURMOUNT-OSA’s large AHI reductions — gives sleep-apnea patients a diagnosis-anchored path through plans that exclude “weight loss” as a category; documentation strategy in the OSA file. Wegovy’s edges: the SELECT cardiovascular-outcomes indication does the same unlocking for established-CVD patients, and semaglutide is the only one of the pair with an oral weight-label form (the Wegovy tablet, December 2025) for the needle-averse — with Foundayo now competing for that same patient. Kidney-outcomes data (FLOW, in diabetes) rounds out semaglutide’s organ-protection résumé. Translation: your comorbidity chart can rationally outvote the efficacy delta — a CVD patient whose plan covers Wegovy-with-PA has a better real-world option than a cash-pay Zepbound aspiration.
The 2026 price ladders — same coverage lanes, different traps
Shared lanes: both sit in the $50 Medicare Bridge (Zepbound via KwikPen; BMI tiers apply) and both run ~$25 commercial savings cards — covered lanes first, always. Self-pay, Zepbound: LillyDirect single-dose vials at $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) — with the ladder’s teeth in the refill clock: miss the 45-day window and the top doses reprice to $849–$1,049; the KwikPen channel has run materially higher in some outlets. Self-pay, Wegovy: NovoCare’s starter promos (reported $199 first fills) stepping to the ~$349-class, with the tablet’s lowest dose near $149 as the entry teaser. The structural read: both ladders are dose-tiered with promotional doors — price the dose you’ll maintain, price the missed-month scenario, and treat every figure as dated (the coverage decoder tracks the moving parts, TrumpRx snapshots included).
Who should pick which — the four-question sort
One: does a label match your chart? OSA → Zepbound’s lever; established CVD → Wegovy’s. Two: what does your plan actually cover? A covered anything beats an uncovered everything — formulary reality outranks trial deltas. Three: how much loss does your goal require? Chasing maximum loss with no coverage constraints → the SURMOUNT-5 verdict points to tirzepatide; a 10–12% target puts both (and the pill) in range. Four: needles? Only semaglutide offers the no-injection brand path today. And if you’re switching mid-course rather than starting, the switching file’s re-titration and re-baseline rules apply — upgrades are real, but they’re managed transitions, not pharmacy swaps.
Ozempic vs Mounjaro — the same duel in diabetes clothing
Same molecules, different labels: Ozempic (semaglutide) and Mounjaro (tirzepatide) carry type-2-diabetes indications with their own dose ceilings and — crucially — different coverage physics: T2D coverage is far more routine than obesity coverage, which is why these names dominate real-world use. The honest boundaries: the efficacy relationship mirrors the weight-label verdict (tirzepatide’s glycemic and weight results led its class); prescribing them for weight without a diabetes diagnosis is off-label use your prescriber and plan adjudicate — and misrepresenting a diagnosis to unlock coverage is fraud, full stop. For a diabetic patient, the choice tracks A1c goals, weight goals, and formulary tier; for a non-diabetic reader, the weight-label section above is your actual decision.
The compounded counterparts — the same verdict at flat prices
The SURMOUNT-5 relationship travels: compounded programs offer the same active ingredients, and the audited flat floor prices the pair at $119–$139/month semaglutide versus $139–$169/month tirzepatide — dose-proof, month-to-month — making the tirzepatide premium about $20–$30/month for the higher-efficacy molecule rather than brand’s $100-class gap: both molecules, audited flat ↗ (compounded; same active ingredients as brand; not FDA-approved as finished drugs). The full brand-vs-compounded decision — sterility tiers, pharmacy verification, when brand is simply right — lives in the dedicated file and the verification guide; the boards keep every tier labeled and dated at /pricing/.
FAQ
Which causes more weight loss, Zepbound or Wegovy?
Zepbound — the head-to-head SURMOUNT-5 trial reported ~20.2% vs ~13.7% average loss at 72 weeks at maximum tolerated dosing, with individual variation on both arms.
Is Zepbound or Wegovy cheaper in 2026?
Covered lanes tie (~$25 cards; $50 Medicare Bridge for both). Self-pay: Zepbound vials run $299–$449 with an $849–$1,049 repricing trap outside the 45-day refill window; Wegovy’s lane runs promo-then-~$349-class. Price your maintenance dose, dated.
When does Wegovy beat Zepbound?
When labels or logistics flip the board: established cardiovascular disease (SELECT indication), a plan that covers Wegovy but not Zepbound, or a hard no on needles — semaglutide alone has an oral brand form today.
Ozempic vs Mounjaro — same answer?
Same molecules under diabetes labels: the efficacy relationship mirrors SURMOUNT-5, coverage is typically easier under a genuine T2D diagnosis, and weight-only use of the diabetes brands is off-label territory for your prescriber and plan — never a coding game.